154 related articles for article (PubMed ID: 36892631)
1. Safety of pitolisant: a study in the WHO international pharmacovigilance database.
Montastruc JL
Eur J Clin Pharmacol; 2023 Apr; 79(4):569-570. PubMed ID: 36892631
[No Abstract] [Full Text] [Related]
2. Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database.
Bettuzzi T; Drucker A; Staumont-Sallé D; Bihan K; Lebrun-Vignes B; Sbidian E
J Am Acad Dermatol; 2022 Feb; 86(2):431-433. PubMed ID: 34600034
[No Abstract] [Full Text] [Related]
3. Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database.
Campillo JT; Faillie JL
Therapie; 2022; 77(6):747-749. PubMed ID: 35606189
[No Abstract] [Full Text] [Related]
4. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
Kim MS; Jung SY; Lee SW; Li H; Koyanagi A; Kronbichler A; Dragioti E; Tizaoui K; Wasuwanich P; Hong SH; Ghayda RA; Yoo HW; Kim H; Jacob L; Salem JE; Kostev K; Shin YH; Kim SY; Gamerith G; Yon DK; Shin JI; Smith L
Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1970-1972.e3. PubMed ID: 33940227
[TBL] [Abstract][Full Text] [Related]
5. Changing spectrum of suspected drugs of epidermal necrolysis: A World Health Organization pharmacovigilance database analysis from 1997-2020.
Bettuzzi T; Ingen-Housz-Oro S; Purtillo CC; Le Cleach L; Maison P; de Prost N; Wolkenstein P; Lebrun-Vignes B; Sbidian E
J Am Acad Dermatol; 2021 Dec; 85(6):1581-1584. PubMed ID: 33217509
[No Abstract] [Full Text] [Related]
6. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
8. Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019.
Montastruc JL
Br J Clin Pharmacol; 2023 Jan; 89(1):201-208. PubMed ID: 35881623
[TBL] [Abstract][Full Text] [Related]
9. Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase.
Roselli A; Khouri C; Roustit M; Blaise S; Cracowski JL
Dermatol Surg; 2019 Dec; 45(12):1517-1528. PubMed ID: 30829775
[TBL] [Abstract][Full Text] [Related]
10. Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety.
Jiang C; Qian J; Jiang X; Zhang S; Zheng J; Wang H
Pharmacol Res Perspect; 2024 Feb; 12(1):e1161. PubMed ID: 38174838
[TBL] [Abstract][Full Text] [Related]
11. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
12. Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Kröger E; Mouls M; Wilchesky M; Berkers M; Carmichael PH; van Marum R; Souverein P; Egberts T; Laroche ML
Ann Pharmacother; 2015 Nov; 49(11):1197-206. PubMed ID: 26324356
[TBL] [Abstract][Full Text] [Related]
13. Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.
Wakao R; Taavola H; Sandberg L; Iwasa E; Soejima S; Chandler R; Norén GN
Drug Saf; 2019 Dec; 42(12):1487-1498. PubMed ID: 31559542
[TBL] [Abstract][Full Text] [Related]
14. Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?
Noguchi Y; Yoshimura T
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5737. PubMed ID: 37985422
[No Abstract] [Full Text] [Related]
15. Characterization of drug-induced cutaneous lupus: Analysis of 1994 cases using the WHO pharmacovigilance database.
Kawka L; Mertz P; Chasset F; Lebrun-Vignes B; Salem JE; Arnaud L
Autoimmun Rev; 2021 Jan; 20(1):102705. PubMed ID: 33188917
[No Abstract] [Full Text] [Related]
16. Identification of risk factors for adverse drug reactions in a pharmacovigilance database.
Attelind S; Eriksson N; Sundström A; Wadelius M; Hallberg P
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5753. PubMed ID: 38169128
[No Abstract] [Full Text] [Related]
17. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
[TBL] [Abstract][Full Text] [Related]
18. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase
Linselle M; Sommet A; Bondon-Guitton E; Moulis F; Durrieu G; Benevent J; Rousseau V; Chebane L; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2017 Jun; 31(3):359-366. PubMed ID: 28036099
[TBL] [Abstract][Full Text] [Related]
19. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
20. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
